Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting

PALO ALTO, Calif.--(BUSINESS WIRE)-- #ILT3--Immune-Onc Therapeutics to Present a Poster on IO-202 Phase 1 Study in Patients with Advanced Solid Tumors at SITC 2022

Click to view original post